Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils
- PMID: 23132816
- PMCID: PMC3572335
- DOI: 10.1002/stem.1270
Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils
Abstract
The use of mesenchymal stromal cells (MSCs) for treatment of bacterial infections, including systemic processes like sepsis, is an evolving field of investigation. This study was designed to investigate the potential use of MSCs, harvested from compact bone, and their interactions with the innate immune system, during polymicrobial sepsis induced by cecal ligation and puncture (CLP). We also wanted to elucidate the role of endogenous heme oxygenase (HO)-1 in MSCs during a systemic bacterial infection. MSCs harvested from the bones of HO-1 deficient (-/-) and wild-type (+/+) mice improved the survival of HO-1(-/-) and HO-1(+/+) recipient mice when administered after the onset of polymicrobial sepsis induced by CLP, compared with the administration of fibroblast control cells. The MSCs, originating from compact bone in mice, enhanced the ability of neutrophils to phagocytize bacteria in vitro and in vivo and to promote bacterial clearance in the peritoneum and blood after CLP. Moreover, after depleting neutrophils in recipient mice, the beneficial effects of MSCs were entirely lost, demonstrating the importance of neutrophils for this MSC response. MSCs also decreased multiple organ injury in susceptible HO-1(-/-) mice, when administered after the onset of sepsis. Taken together, these data demonstrate that the beneficial effects of treatment with MSCs after the onset of polymicrobial sepsis is not dependent on endogenous HO-1 expression, and that neutrophils are crucial for this therapeutic response.
Copyright © 2012 AlphaMed Press.
Conflict of interest statement
The authors indicate no potential conflicts of interest.
Figures







Similar articles
-
Immunophenotypic characterization and therapeutics effects of human bone marrow- and umbilical cord-derived mesenchymal stromal cells in an experimental model of sepsis.Exp Cell Res. 2021 Feb 15;399(2):112473. doi: 10.1016/j.yexcr.2021.112473. Epub 2021 Jan 8. Exp Cell Res. 2021. PMID: 33428902
-
Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes.Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L1003-13. doi: 10.1152/ajplung.00180.2011. Epub 2012 Mar 16. Am J Physiol Lung Cell Mol Physiol. 2012. PMID: 22427530 Free PMC article.
-
Mesenchymal stromal cells expressing a dominant-negative high mobility group A1 transgene exhibit improved function during sepsis.J Leukoc Biol. 2021 Oct;110(4):711-722. doi: 10.1002/JLB.4A0720-424R. Epub 2021 Jan 13. J Leukoc Biol. 2021. PMID: 33438259 Free PMC article.
-
[Research progress in mesenchymal stem cells modified by Heme oxygenase 1].Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2019 Jul 15;33(7):901-906. doi: 10.7507/1002-1892.201812079. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2019. PMID: 31298011 Free PMC article. Review. Chinese.
-
Mesenchymal stem/stromal cells as a therapeutic for sepsis: a review on where do we stand?Stem Cell Res Ther. 2025 May 15;16(1):245. doi: 10.1186/s13287-025-04371-w. Stem Cell Res Ther. 2025. PMID: 40375314 Free PMC article. Review.
Cited by
-
Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation.J Immunol Res. 2016;2016:7121580. doi: 10.1155/2016/7121580. Epub 2016 Jul 27. J Immunol Res. 2016. PMID: 27529074 Free PMC article. Review.
-
Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials.J Biomed Sci. 2016 Nov 4;23(1):76. doi: 10.1186/s12929-016-0289-5. J Biomed Sci. 2016. PMID: 27809910 Free PMC article. Review.
-
Comparison of Antibacterial and Immunological Properties of Mesenchymal Stem/Stromal Cells from Equine Bone Marrow, Endometrium, and Adipose Tissue.Stem Cells Dev. 2018 Nov 1;27(21):1518-1525. doi: 10.1089/scd.2017.0241. Epub 2018 Sep 6. Stem Cells Dev. 2018. PMID: 30044182 Free PMC article.
-
Diabetic microenvironment preconditioning of adipose tissue-derived mesenchymal stem cells enhances their anti-diabetic, anti-long-term complications, and anti-inflammatory effects in type 2 diabetic rats.Stem Cell Res Ther. 2022 Aug 19;13(1):422. doi: 10.1186/s13287-022-03114-5. Stem Cell Res Ther. 2022. PMID: 35986406 Free PMC article.
-
Mouse Bone Marrow Sca-1+ CD44+ Mesenchymal Stem Cells Kill Avirulent Mycobacteria but Not Mycobacterium tuberculosis through Modulation of Cathelicidin Expression via the p38 Mitogen-Activated Protein Kinase-Dependent Pathway.Infect Immun. 2017 Sep 20;85(10):e00471-17. doi: 10.1128/IAI.00471-17. Print 2017 Oct. Infect Immun. 2017. PMID: 28739828 Free PMC article.
References
-
- Friedenstein AJ, Chailakhyan RK, Latsinik NV, et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17:331–340. - PubMed
-
- Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71–74. - PubMed
-
- Dennis JE, Merriam A, Awadallah A, et al. A quadripotential mesenchymal progenitor cell isolated from the marrow of an adult mouse. J Bone Miner Res. 1999;14:700–709. - PubMed
-
- Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–147. - PubMed
-
- da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119:2204–2213. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous